In a report released today, Ami Fadia from Needham maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $35.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ami Fadia has given his Buy rating due to a combination of factors that highlight the promising outlook for Centessa Pharmaceuticals. The recent updates on the ORX750’s Phase 2a trials have shown significant clinical benefits across various conditions such as NT1, NT2, and IH, which have considerably reduced the risks associated with the program. The efficacy results for NT1 are comparable to existing treatments and even surpass some competitors, while the results for NT2 and IH are also compelling, demonstrating improvements in multiple endpoints.
Moreover, the safety profile of ORX750, with ongoing dose escalation, suggests the potential for a best-in-class profile with manageable side effects compared to competitors. The initiation of Phase 3 trials in the first quarter of 2026 further supports the positive outlook. This progress not only benefits Centessa Pharmaceuticals but also positively impacts the OX2R class in NT2/IH, which is advantageous for other companies like ALKS and HRMY.
In another report released on October 28, Stephens also initiated coverage with a Buy rating on the stock with a $35.00 price target.